Sigilon Therapeutics, Inc. announced the appointment of Eric Shaff, Chief Financial Officer of Seres Therapeutics to the company's board of directors. Mr. Shaff brings a long history of industry experience to the company's board. Eric Shaff is Executive Vice President and Chief Financial Officer of Seres Therapeutics. Prior to Seres, Mr. Shaff worked at Momenta Pharmaceuticals and Genzyme Corporation, where he served as global head of finance of Genzyme's Rare Genetic Disease Division in addition to roles in corporate development and corporate finance. Mr. Shaff has also worked in corporate finance at Pfizer and in investment banking with Broadview International.